In June 2012, Arena’s first commercial product, BELVIQ® (lorcaserin HCl), was approved by the FDA for chronic weight management, and is currently under review for regulatory approval in additional jurisdictions. Arena is also developing oral drug candidates for cardiovascular disease, inflammation and other disorders.